Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Inclusion Criteria

• •Restricted to 18 to 80 years of age
• •Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
• •Histologic confirmation of gastric adenocarcinoma including all subtypes and Siewert type II/III gastroesophageal (GE) junction adenocarcinomas
• •Absolute neutrophil count \>= 1,500 / uL
• •Platelets \>= 50,000 / Ul
• •Serum creatinine \<= 1.5 mg / dL
• •Adequate nutritional status (Albumin \>= 3.5)
• •Metastasis confined to the peritoneum:
• •* Positive peritoneal cytology
• •* Peritoneal metastasis on diagnostic laparoscopy
• •* Peritoneal metastasis on imaging
• •Response to systemic chemotherapy defined as at least one of the following:
• •* Reduction (\>= 30%) in standardized uptake value (SUV) max \[Response Evaluation Criteria in Solid Tumors (RECIST) criteria\]
• •* Reduction in size of primary tumor, regional lymph node or peritoneal metastasis on imaging (\>= 20% decrease in the longest diameter of target lesion) RECIST criteria
• •* Reduction ( \>= 30%) in Peritoneal Carcinomatosis Index (PCI) or conversion of peritoneal cytology
• •* Reduction ( \>= 30%) in serum tumor markers CEA or CA 19-9
• •Peritoneal Carcinomatosis Index (PCI) =\< 7 and surgeon deems high likelihood for a complete cytoreduction
• •Body Mass Index (BMI) =\< 35 kg/m\^2